Ranibizumab + laser — Competitive Intelligence Brief

Ranibizumab + laser (Ranibizumab + laser) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

phase 3 VEGF inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology Small molecule

Target snapshot

Ranibizumab + laser (Ranibizumab + laser) — Jaeb Center for Health Research. Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranibizumab + laser TARGET	Ranibizumab + laser	Jaeb Center for Health Research	phase 3	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Ranibizumab (Lucentis)	Ranibizumab (Lucentis)	Greater Houston Retina Research	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody fragment) class)

1. Hospital Regional de São José - Dr. Homero de Miranda Gomes · 1 drug in this class
2. Jaeb Center for Health Research · 1 drug in this class
3. Retinal Consultants of Arizona · 1 drug in this class
4. University Hospital Muenster · 1 drug in this class